Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables (2016 - 2025)

Historic Receivables for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $137.7 million.

  • Adma Biologics' Receivables rose 17457.72% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 17457.72%. This contributed to the annual value of $50.0 million for FY2024, which is 8233.84% up from last year.
  • Latest data reveals that Adma Biologics reported Receivables of $137.7 million as of Q3 2025, which was up 17457.72% from $109.7 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Receivables peaked at $137.7 million during Q3 2025, and registered a low of $15.4 million during Q1 2021.
  • Its 5-year average for Receivables is $43.0 million, with a median of $28.6 million in 2021.
  • In the last 5 years, Adma Biologics' Receivables tumbled by 4574.28% in 2022 and then soared by 26438.08% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Receivables stood at $28.6 million in 2021, then crashed by 45.74% to $15.5 million in 2022, then soared by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then skyrocketed by 175.35% to $137.7 million in 2025.
  • Its Receivables stands at $137.7 million for Q3 2025, versus $109.7 million for Q2 2025 and $99.4 million for Q1 2025.